logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 20 of 20 Items
Showing 1 - 20 of 20 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (20)
  • CSV
  • BibTeX
  • EndNote
  • All Results (20)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W,  et al.
2025-08-22 • Clinical Infectious Diseases
2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

Journal Article
|
Research
Conference Material
|
Abstract

Implementation of treatment-decision algorithms for children with pulmonary tuberculosis: cross-cutting lessons for operational scale-up

Conference Material
|
Slide Presentation

Implementation of treatment-decision algorithms for children with pulmonary tuberculosis: cross-cutting lessons for operational scale-up

Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Commentary
Journal Article
|
Editorial
Journal Article
|
Research
Journal Article
|
Research
Conference Material
|
Poster
Conference Material
|
Poster
Conference Material
|
Poster
Journal Article
|
Research
Conference Material
|
Poster
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Technical Report
|
Study report

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Armour-Marshall J, Scarpa G, Abdullahi MB, Farouk Moussa Mamane O, Fidelle Nyikayo L,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025
Armour-Marshall J, Scarpa G, Abdullahi MB, Farouk Moussa Mamane O, Fidelle Nyikayo L,  et al.
2025-05-22 • MSF Scientific Days International 2025
2025-05-22 • MSF Scientific Days International 2025

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A,  et al.
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Leveraging nutritional rehabilitation and tuberculosis programmes to tackle tuberculosis and severe acute malnutrition in children

Vonasek BJ, Marcy O, Armour J, Casenghi M, Cazes C,  et al.
2025-03-23 • Lancet Child and Adolescent Health
2025-03-23 • Lancet Child and Adolescent Health

Each day more than 500 children younger than 15 years die from tuberculosis. Considerable progress has been...

Scanned: The global investments in computer-aided detection and ultraportable X-ray for tuberculosis

Min J, Halton J, Villegas C, Chua A, Hewison C,  et al.
2025-03-17 • PLOS Global Public Health
2025-03-17 • PLOS Global Public Health

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A,  et al.
2025-03-01 • IJTLD OPEN
2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R,  et al.
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health

BACKGROUND

There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Community experiences of TB in the Philippines: Using storytelling to improve community knowledge of TB and uptake of screening in an urban slum

Solaiman AP, Venables E, Roxas MRC, Mateo M, Castro R,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024

Increased access and attention to toxicity: lessons learnt from the first cohort of 6-month drug resistant tuberculosis regimens in Gujranwala, Pakistan

Muhammad S, Sannino L, Ahumuza V, Fatima H, Imtiaz S,  et al.
2024-11-08 • MSF Scientific Days Asia 2024
2024-11-08 • MSF Scientific Days Asia 2024

Diagnosing tuberculosis in children using the new WHO algorithm in Niger

Farouk Moussa Mamane O, Sannino L, Alphazazi S, Rabiou D, Hewison C
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY,  et al.
2024-05-09 • Nature Communications
2024-05-09 • Nature Communications
Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...

Diagnostic performance and feasibility of two new treatment decision algorithms for pulmonary tuberculosis in children: A diagnostic and mixed-methods multi-country study

Abdullahi MB, Issa-Soumana A-M, Namulwana ML, Barry I, Fidelle Nyikayo L,  et al.
2024-05-03 • MSF Paediatric Days 2024
2024-05-03 • MSF Paediatric Days 2024

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD,  et al.
2024-01-20 • medRxiv
2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S,  et al.
2020-07-11 • Clinical Infectious Diseases
2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Culture conversion in patients treated with bedaquiline and/or delamanid. A prospective multicountry study

Franke MF, Khan P, Hewison C, Khan U, Huerga H,  et al.
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion

Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C,  et al.
2022-11-10 • PLOS One
2022-11-10 • PLOS One

BACKGROUND

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns

Atwood S, Avagyan N, Bastard M, Cain M, Collin S,  et al.
2018-07-01
2018-07-01